Search
Search Results
##search.searchResults.foundPlural##
-
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
3971PDF: 1113HTML: 1914Fig.1: 204Fig. 2: 101Table 1: 183Table2: 199Table 3: 180 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4206PDF: 1704HTML: 1095 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
1968PDF: 1458HTML: 258 -
ADVANCES IN THE TREATMENT OF MALARIA
2778PDF: 1091HTML: 5976 -
GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey
1271PDF: 869Suppl. Files: 430HTML: 218 -
-
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
917PDF: 328HTML: 78 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7194PDF: 2368HTML: 1703Table 1.: 183Table 2.: 199Table 3.: 179Table 4.: 178 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4533PDF: 2729HTML: 2244 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2692PDF: 1069HTML: 3252 -
LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
1217PDF: 866HTML: 1243fig 1A: 153figure1B: 127 -
BACTERIAL INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
3024PDF: 1768HTML: 3540 -
APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA
1616PDF: 623HTML: 2413 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3825PDF: 1438HTML: 9170Untitled: 257Untitled: 162Untitled: 149Untitled: 143Untitled: 163Untitled: 316 -
ASSESSMENT OF THE EFFICACY OF PROCALCITONIN, C-REACTIVE PROTEIN AND ALBUMIN LEVELS-GUIDED ANTIBIOTICS USE IN SEPSIS
860PDF: 439Html: 128Suppl. Files: 146 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1154PDF: 923HTML: 190 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2168PDF: 1002HTML: 1971Characteristic of study group: 177 -
PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
2883PDF: 939HTML: 2050Cover letter: 160 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2804PDF: 1308HTML: 3551Untitled: 171Untitled: 184Untitled: 160 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1599PDF: 1124HTML: 229 -
OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION
1022PDF: 524HTML: 1673Figures: 144Fifures Sanz: 156tables Sanz: 163Untitled: 157 -
SOLITARY PLASMACYTOMA
3743PDF: 2126HTML: 1194fIGURES 1,2: 189







